159 related articles for article (PubMed ID: 38019741)
1. [The infinite potential of a single substance: The history of tamoxifen as an example of drug repositioning].
Spławska K; Wilanowski T
Postepy Biochem; 2023 Sep; 69(3):222-231. PubMed ID: 38019741
[TBL] [Abstract][Full Text] [Related]
2. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives.
Shagufta ; Ahmad I
Eur J Med Chem; 2018 Jan; 143():515-531. PubMed ID: 29207335
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
5. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
Jordan VC
Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
[TBL] [Abstract][Full Text] [Related]
6. HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
Wege AK; Chittka D; Buchholz S; Klinkhammer-Schalke M; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
Breast Cancer Res; 2018 Nov; 20(1):139. PubMed ID: 30458882
[TBL] [Abstract][Full Text] [Related]
7. Research progress on tamoxifen and its analogs associated with nuclear receptors.
Dong N; Du Y; Zheng Y; Zhang H; Lv H; Yan Z
Future Med Chem; 2023 Aug; 15(15):1427-1442. PubMed ID: 37706220
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
Dhingra K
Cancer Invest; 2001; 19(6):649-59. PubMed ID: 11486708
[TBL] [Abstract][Full Text] [Related]
9. Progress in the prevention of breast cancer: concept to reality.
Jordan VC
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen resistance: from bench to bedside.
Droog M; Beelen K; Linn S; Zwart W
Eur J Pharmacol; 2013 Oct; 717(1-3):47-57. PubMed ID: 23545365
[TBL] [Abstract][Full Text] [Related]
11. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer.
Tonetti DA; Jordan VC
J Steroid Biochem Mol Biol; 1997 Jun; 62(2-3):119-28. PubMed ID: 9393947
[TBL] [Abstract][Full Text] [Related]
12. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
Jordan VC; Obiorah I; Fan P; Kim HR; Ariazi E; Cunliffe H; Brauch H
Breast; 2011 Oct; 20 Suppl 3(Suppl 3):S1-11. PubMed ID: 22015273
[TBL] [Abstract][Full Text] [Related]
13. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
Mishra RR; Belder N; Ansari SA; Kayhan M; Bal H; Raza U; Ersan PG; Tokat ÜM; Eyüpoğlu E; Saatci Ö; Jandaghi P; Wiemann S; Üner A; Cekic C; Riazalhosseini Y; Şahin Ö
Clin Cancer Res; 2018 Apr; 24(8):1987-2001. PubMed ID: 29386221
[No Abstract] [Full Text] [Related]
15. Antiestrogens--tamoxifen, SERMs and beyond.
Dhingra K
Invest New Drugs; 1999; 17(3):285-311. PubMed ID: 10665480
[TBL] [Abstract][Full Text] [Related]
16. Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
Cappelletti V; Veneroni S; Coradini D; Oriana S; Tomasic G; Younes M; Daidone MG
J Natl Cancer Inst; 2003 Apr; 95(8):629-30. PubMed ID: 12697859
[No Abstract] [Full Text] [Related]
17. The fight against tamoxifen resistance in breast cancer therapy: a new target in the battle?
Nichols M
Mol Interv; 2007 Feb; 7(1):13-6. PubMed ID: 17339602
[TBL] [Abstract][Full Text] [Related]
18. Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66.
Farahmand L; Mansouri S; Jafarbeik-Iravani N; Teymourzadeh A; Majidzadeh-A K
Recent Pat Anticancer Drug Discov; 2018; 13(3):302-307. PubMed ID: 29512469
[TBL] [Abstract][Full Text] [Related]
19. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches.
Nobert GS; Kraak MM; Crawford S
Bull Cancer; 2006 Jul; 93(7):E59-66. PubMed ID: 16873071
[TBL] [Abstract][Full Text] [Related]
20. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]